Hypera S.A. (OTCMKTS:HYPMY) Sees Large Growth in Short Interest

Hypera S.A. (OTCMKTS:HYPMY) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 5,800 shares, a growth of 5,700.0% from the March 15th total of 100 shares. Based on an average daily trading volume, of 19,500 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.0% of the shares of the stock are sold short.

Hypera Stock Performance

Hypera stock opened at $3.29 on Wednesday. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.68. The stock has a market cap of $2.08 billion, a PE ratio of 8.23 and a beta of 0.75. Hypera has a 12-month low of $2.64 and a 12-month high of $6.03. The business’s 50-day moving average price is $3.38 and its two-hundred day moving average price is $3.52.

Hypera (OTCMKTS:HYPMY) last released its quarterly earnings data on Thursday, March 20th. The company reported $0.02 earnings per share (EPS) for the quarter. Hypera had a net margin of 20.04% and a return on equity of 13.18%. The business had revenue of $258.56 million during the quarter.

Hypera Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.